li001

New Study Reveals Why Small Cell Lung Cancer Spreads and Relapses So Rapidly

Research Advances /

Researchers have discovered why Small Cell Lung Cancer is so aggressive and likely to relapse. They found that these cancer cells are missing a key protein called caspase-8, which normally helps cells die in a controlled way. Without it, the cells die through a different process called necroptosis, which triggers inflammation. This inflammation creates a […]

New Study Reveals Why Small Cell Lung Cancer Spreads and Relapses So Rapidly Read More »

CD22 CAR T Therapy Offers Lifesaving Option for Children and Young Adults with Relapsed B-ALL

Treatment /

Final results from a decade-long National Cancer Institute study show that CD22-targeted CAR T-cell therapy is a highly effective salvage treatment for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL), especially those who relapsed after CD19 therapies. Many relapses occur because leukemia cells lose CD19 expression, a problem called antigen escape. Targeting CD22

CD22 CAR T Therapy Offers Lifesaving Option for Children and Young Adults with Relapsed B-ALL Read More »

Trastuzumab Rezetecan Shows Strong Activity in HER2-Positive Gastric and Colorectal Cancers

Clinical Trails /

A Phase 1 trial shows that trastuzumab rezetecan (SHR-A1811), a next-generation antibody-drug conjugate (ADC), is effective and well-tolerated in patients with HER2-expressing gastric (GC/GEJ) and colorectal cancers (CRC). Trastuzumab rezetecan works like a “smart bomb”: the HER2-targeting antibody directs the drug to cancer cells, while a linked chemotherapy payload is released inside tumors, limiting damage

Trastuzumab Rezetecan Shows Strong Activity in HER2-Positive Gastric and Colorectal Cancers Read More »

Axatilimab Shows Strong Real-World Results for Severe, Treatment-Resistant cGVHD

Research Advances /

Real-world data show that axatilimab (Niktimvo) is highly effective for patients with severe, treatment-resistant chronic graft-versus-host disease (cGVHD). The analysis included 104 patients, most of whom had severe disease affecting multiple organs and had tried a median of four prior therapies, including ruxolitinib (Jakafi) and belumosudil (Rezurock). Pediatric patients under 17 made up 10.6% of

Axatilimab Shows Strong Real-World Results for Severe, Treatment-Resistant cGVHD Read More »

Sunvozertinib Outperforms Chemotherapy for Rare EGFR-Mutant Lung Cancer

Treatment /

The Phase 3 WU-KONG28 trial shows that sunvozertinib (Zegfrovy) is more effective than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. Sunvozertinib significantly delayed cancer growth, offering superior progression-free survival compared with traditional platinum-based chemotherapy. It also outperformed chemotherapy in overall response and disease control rates,

Sunvozertinib Outperforms Chemotherapy for Rare EGFR-Mutant Lung Cancer Read More »

Obe-cel CAR T Therapy Shows Long-Term Survival Benefits in Relapsed B-ALL

Treatment /

Relapsed B-ALL A post hoc analysis of the Phase 1b/2 FELIX trial shows that obecabtagene autoleucel (obe-cel; Aucatzyl) can provide long-term survival for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), regardless of the type of remission achieved. Patients who reached complete remission (CR) or complete remission with incomplete blood count recovery (CRi)

Obe-cel CAR T Therapy Shows Long-Term Survival Benefits in Relapsed B-ALL Read More »

New Targeted Therapy VIC-1911 Shows Promise in Preventing Relapse After Stem Cell Transplant

Clinical Trails /

A Phase 1 clinical trial suggests that adding the targeted drug VIC-1911 to standard care after donor stem cell transplants may greatly improve outcomes for patients with blood cancers. After a transplant, doctors must balance preventing graft-versus-host disease (GVHD), where donor immune cells attack the patient, while preserving the graft-versus-tumor effect that helps destroy cancer.

New Targeted Therapy VIC-1911 Shows Promise in Preventing Relapse After Stem Cell Transplant Read More »

Selinexor Combo Improves Spleen Reduction in Phase 3 Myelofibrosis Trial

Clinical Trails /

The Phase 3 SENTRY trial shows that adding selinexor (Xpovio) to ruxolitinib (Jakafi) improves outcomes for patients newly treated for myelofibrosis, especially in reducing spleen size. At 24 weeks, 50% of patients receiving the combination therapy achieved at least a 35% reduction in spleen volume, compared with 28% of those taking ruxolitinib alone. However, the

Selinexor Combo Improves Spleen Reduction in Phase 3 Myelofibrosis Trial Read More »

CAR T-Cell Therapy YTB323 Shows High Response Rates in Advanced B-ALL Trial

Targeted Therapy /

Data show that rapcabtagene autoleucel (YTB323), a next-generation CAR T-cell therapy, is highly effective in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). In the Phase 1/2 study, the overall response rate reached 86% within three months. All responding patients achieved minimal residual disease (MRD) negativity, meaning no detectable cancer remained. With a

CAR T-Cell Therapy YTB323 Shows High Response Rates in Advanced B-ALL Trial Read More »

CAR T-Cell Therapy YTB323 Shows High Response Rates in Advanced B-ALL Trial

Targeted Therapy /

Data show that rapcabtagene autoleucel (YTB323), a next-generation CAR T-cell therapy, is highly effective in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). In the Phase 1/2 study, the overall response rate reached 86% within three months. All responding patients achieved minimal residual disease (MRD) negativity, meaning no detectable cancer remained. With a

CAR T-Cell Therapy YTB323 Shows High Response Rates in Advanced B-ALL Trial Read More »